Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2025-05-15
Target enrollment:
Participant gender:
Summary
The trial is a single-center, single-arm, prospective clinical study with a planned
enrollment of 15 patients with primary Multiple myeloma(MM), aiming to investigate the
efficacy and safety of maintenance therapy with Pomalidomide in patients with primary MM.
Patients enrolled were divided into two categories: 1) patients suitable for Autologous
Hematopoietic Stem Cell Transplantation(ASCT) started pomalidomide maintenance therapy 3
months after ASCT; 2) patients not suitable for ASCT started pomalidomide maintenance therapy
after induction and consolidation therapy to achieve maximum efficacy. Dosing on days 1-21, 2
mg daily for 28 days as a cycle, for a total duration of 36 months or the onset of disease
progression, intolerable adverse events. 2-year progression-free survival (2y-PFS) was used
as the primary study endpoint, 2-year overall survival (2y-OS), complete remission rate (CR),
very good partial remission rate (VGPR), and negative rate of minimal residual disease(MRD)
were secondary study endpoints, and the incidence of adverse events (AEs) was assessed.